Halozyme Therapeutics vs Repligen

Halozyme Therapeutics (HALO), health care, and Repligen (RGEN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Halozyme Therapeutics is worth $10.9B on the stock market and Repligen $10.4B: Halozyme Therapeutics is valued at 6% more. Halozyme Therapeutics's operating margin in its latest fiscal year was 33.6% and Repligen's 7.47%. Over the past year Halozyme Therapeutics's share price has moved +37.7% and Repligen's +6.35%.

Key facts

Halozyme Therapeutics market value
$10.9B
Repligen market value
$10.4B
Halozyme Therapeutics P/E
24.0
Halozyme Therapeutics revenue
$1.4BFY to 2025-12-31
Repligen revenue
$738.3MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Halozyme Therapeutics vs Repligen: every measure side by side
Measure Halozyme Therapeutics Repligen
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.9Bhigher$10.4Blower
Revenue$1.4Bhigher$738.3Mlower
Earnings$316.9Mhigher$48.9Mlower
Employees423lower2,000higher
Total assets$2.5Blower$2.9Bhigher
Valuation
P/E24.0—
P/S7.8lower14.0higher
P/B—4.4
Dividend yield0.00%0.00%
Profitability
Operating margin33.6%higher7.47%lower
Balance sheet
Net assets$48.8Mlower$2.1Bhigher
Total liabilities$2.5Bhigher$843.6Mlower
Total debt$2.1Bhigher$542.2Mlower
Cash on hand$133.8Mlower$566Mhigher
Price change
Today-0.55%lower-0.37%higher
1 year+37.7%higher+6.35%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns HALO · Who owns RGEN

Further comparisons

Learn

Questions and answers

Which is bigger, Halozyme Therapeutics or Repligen?

By market value, Halozyme Therapeutics is the larger: $10.9B against $10.4B for Repligen. By revenue in its latest fiscal year, Halozyme Therapeutics is the larger: $1.4B against $738.3M for Repligen.

Which has the higher operating margin?

Halozyme Therapeutics: 33.6%, against 7.47% for Repligen. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Halozyme Therapeutics: $2.1B, against $542.2M for Repligen. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Halozyme Therapeutics and Repligen?

None of the tracked superinvestors holds both in their latest 13F filing. 5 hold Halozyme Therapeutics and 6 hold Repligen.

Cite this page

Funkfolio, “Halozyme Therapeutics vs Repligen”, data as of 18 November 2026. https://funkfolio.com/compare/halo-vs-rgen

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.